1. OP01 Withdrawal of infliximab or anti-metabolite therapy in Crohn's Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE). (21st January 2022) Authors: Louis J, E; Resche-Rigon, M; Laharie, D; Satsangi, J; Ding, N; Preiss, J; D'Haens, G; Picon, L; Bossuyt, P; Vuitton, L; Irving, P; Bouhnik, Y; Viennot, S; Lamb, C; Pollock, R; Baert, F; Nachury, M; Mathurin, F; Gilletta, C; Colombel, J F Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP02 Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn's disease patients stopping infliximab. (30th January 2023) Authors: Pierre, N; Huynh-Thu, V A; Baiwir, D; Mazzucchelli, G; Fléron, M; Trzpiot, L; Eppe, G; Laharie, D; Satsangi, J; Colombel, J F; Hertervig, E; Meuwis, M A; Louis, E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. (25th January 2019) Authors: Yzet, C; Ungaro, R; Bossuyt, P; Baert, F; Vanasek, T; D'Haens, G; Joustra, V; Panaccione, R; Novacek, G; Armuzzi, A; Golovchenko, O; Prymak, O; Goldis, A; Travis, S; Hébuterne, X; Ferrante, M; Rogler, G; Fumery, M; Danese, S; Rydzewska, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S024 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P218 The cost-effectiveness of biological therapy cycles in the management of Crohn's disease. (25th January 2019) Authors: Bolin, K; Louis, E; Hertervig, E Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P595 Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD–GO-SWIBREG. (16th January 2018) Authors: Eriksson, C; Bergemalm, D; Vigren, L; Nilsson, L; Visuri, I; Hjortswang, H; Udumyan, R; Almer, S; Seddighzadeh, M; Hertervig, E; Karlén, P; Strid, H; Halfvarson, J Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P758 Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). (16th January 2018) Authors: Eriksson, C; Rundquist, S; Lykiardopoulos, V; Karlén, P; Grip, O; Söderman, C; Almer, S; Hertervig, E; Gunnarsson, J; Malmgren, C; Delin, J; Strid, H; Sjöberg, M; Öberg, D; Bergemalm, D; Udumyan, R; Hjortswang, H; Halfvarson, J Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗